FLASH SELL: Sell This Stock at More Than 140% Profit – Before It Drops!
The company appears to be preparing investors for less than ideal results for its DNA vaccine VGX-3100, which is in phase 2 trials to treat women who have cervical precancerous cells. Our stock soared after a 4-1 reverse split Friday and the announcement this week of a new trial for immune therapy to treat neck and head cancers. Then it began tumbling after the company’s CEO gave an interview that seemed to be backpedaling expectations.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Breakthrough Technology Alert
This is the best time to be investing in world-changing technologies, as unprecedented innovations are taking off right now… Breakthrough Technology Alert tirelessly researches these exciting new breakthrough technologies to keep you well informed, outline specific opportunities, and keep you ahead of the game.